Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PLYX

Polaryx Therapeutics Inc

Apr 17 • 04:00PM ET

6.12

-0.27 -4.23 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.19	Insider Own	91.81%	Shs Outstand	47.34M	Perf Week	7.75%
Market Cap	289.72M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	0.01%	Shs Float	3.88M	Perf Month	10.67%
Enterprise Value	284.58M	PEG	-	EPS next Q	-0.03	Inst Own	-	Short Float	10.14%	Perf Quarter	-
Income	-8.98M	P/S	-	EPS this Y	36.84%	Inst Trans	42.92%	Short Ratio	0.18	Perf Half Y	-
Sales	0.00M	P/B	63.47	EPS next Y	-133.33%	ROA	-165.04%	Short Interest	0.39M	Perf YTD	-82.51%
Book/sh	0.10	P/C	56.37	EPS next 5Y	-	ROE	-193.70%	52W High	48.91 -87.49%	Perf Year	-
Cash/sh	0.11	P/FCF	-	EPS past 3/5Y	-54.22% -	ROIC	-196.82%	52W Low	2.20 178.06%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.35% 17.21%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	70.40%	Oper. Margin	-	ATR (14)	1.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.55	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.89	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	8.55	EPS Q/Q	-106.54%	SMA20	-3.27%	Beta	-	Target Price	10.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	17.77%	Rel Volume	0.04	Prev Close	6.39
Employees	11	LT Debt/Eq	0.00	Earnings	Feb 25	SMA200	-4.39%	Avg Volume	2.14M	Price	6.12
IPO	Feb 02, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	84,916	Change	-4.23%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-27-26	Initiated	Maxim Group	Buy	$10

Apr-15-26 09:15AM	Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care (GlobeNewswire)
Apr-01-26 08:30AM	Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-17-26 08:30AM	Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) (GlobeNewswire)
Mar-12-26 08:30AM	Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events (GlobeNewswire) -19.27%
Feb-27-26 08:30AM	Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders (GlobeNewswire)
10:26AM	Loading…
Feb-17-26 10:26AM	Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans (Benzinga) +64.32%
08:30AM	Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket Trial (GlobeNewswire)
Feb-10-26 08:30AM	Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium (GlobeNewswire) -24.11%
Feb-05-26 08:30AM	Polaryx Therapeutics Welcomes New Members of the Board of Directors (GlobeNewswire) -28.89%
Feb-04-26 08:40AM	Polaryx to present late-breaker data related to Soteria ahead of trial (TipRanks)
Feb-03-26 08:30AM	Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium as Company Prepares for SOTERIA Trial Launch (GlobeNewswire) -37.29%
Feb-02-26 08:30AM	Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" (GlobeNewswire)

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Landis G. Michael	Chief Financial Officer	Feb 18 '26	Buy	2.79	2,867	7,991	228,225	Feb 20 04:41 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLYX

Polaryx Therapeutics Inc

Upgrade your Finviz experience